Actively Recruiting
Nitrous Oxide in the Treatment of Acute Suicidal Ideation
Led by University of Zurich · Updated on 2025-01-16
85
Participants Needed
1
Research Sites
89 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary aim of the NITOS study is to investigate the potential rapid antisuicidal effects of N2O in the transdiagnostic treatment of suicidal ideation. On day 1, patients will receive either nitrous oxide (50% N2O balanced with oxygen) or placebo (50% oxygen balanced with air). Seven days after the first inhalation, a second inhalation will be performed. All patients will receive N2O at least once during this trial. While the first inhalation will be double-blind, only the patients but not the raters will be blinded to the second inhalation (day 8). For mechanism of action and prediction, a nested biomarker substudy will employ multimodal techniques including analysis of hair and blood samples, and EEG.
CONDITIONS
Official Title
Nitrous Oxide in the Treatment of Acute Suicidal Ideation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to give written informed consent
- Moderate to severe suicidal ideation defined as a score on the Montgomery-Asberg Depression Rating Scale (MADRS) suicide item and a self-report Beck Scale for Suicide Ideation (BSS) items #4 plus #5 score 2
- Plasma homocysteine level 14 mol/l
You will not qualify if you...
- Organic or symptomatic mental disorders (F00-F09; lifetime diagnosis)
- Schizophrenia, schizotypal and delusional disorders (F20-F29; lifetime diagnosis)
- Mental and behavioral disorders due to psychoactive substance use except nicotine and cannabis (F10-F19)
- Non-medical use of inhalational N2O during the last 12 months
- Past intolerance or hypersensitivity to N2O
- Critical illness
- Severe cardiac disease
- Pregnancy or breastfeeding
- Pulmonary hypertension
- Chronic cobalamin or folate deficiency unless treated with folic acid and/or vitamin B12
- Any other medical or neurological condition posing undue risk as judged by investigator
- Treatment with ketamine/esketamine during the last 4 weeks
- Treatment with opioid medications during the last 3 months
- Treatment with vagus nerve stimulation (VNS) or electroconvulsive therapy (ECT) within the last 3 months
- Recent or current use of benzodiazepines exceeding 5 mg lorazepam or equivalent per day
- Any other factors impacting patient safety or compliance as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Psychiatric University Hospital Zurich
Zurich, Switzerland, 8032
Actively Recruiting
Research Team
A
Angelina Frasch
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here